North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82(4):1013–1067

Article  CAS  PubMed  Google Scholar 

White N, Butler PE, Burnstock G (2005) Human melanomas express functional P2X7 receptors. Cell Tissue Res 321(3):411–418

Article  CAS  PubMed  Google Scholar 

Lara R, Adinolfi E, Harwood CA, Philpott M, Barden JA, Di Virgilio F, McNulty S (2020) P2X7 in cancer: from molecular mechanisms to therapeutics. Front Pharmacol 11:793

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harris Z, Donovan MG, Branco GM, Limesand KH, Burd R (2016) Quercetin as an emerging anti-melanoma agent: a four-focus area therapeutic development strategy. Front Nutr 3:48

Article  PubMed  PubMed Central  Google Scholar 

Kanai M, Shinagawa A, Ota M, Virgona N, Yano T (2024) Resveratrol can differentiate human melanoma stem-like cells from spheroids treated with all-trans retinoic acid. Anticancer Res 44(12):5283–5292

Article  PubMed  Google Scholar 

Almatroodi SA, A Alsahli M, SM Aljohani A, Alhumaydhi FA, Babiker AY, Khan AA, Rahmani AH (2022) Potential therapeutic targets of resveratrol, a plant polyphenol, and its role in the therapy of various types of cancer. Molecules 27(9):2665

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sluyter R (2023) Purinergic signalling in physiology and pathophysiology. Int J Mol Sci 24(11):9196

Article  PubMed  PubMed Central  Google Scholar 

Nair SS, Kumar R (2012) Chromatin remodeling in cancer: a gateway to regulate gene transcription. Mol Oncol 6(6):611–619

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pegoraro A, De Marchi E, Ferracin M, Orioli E, Zanoni M, Bassi C, Adinolfi E (2021) P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis 12(12):1088

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianchini MC, Franscescon F, Soares AA, Ansolin V, Pretto KP, da Vieira Cunha ML, de Resen e Silva DT (2025) Potential benefits of quercetin through P2X7 modulation against neuroinflammation in Alzheimer’s disease. Curr Neuropharmacol 23(11):1367–1379

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoinoiu T, Dumitrascu V, Pit D, Schipor DA, Jabri-Tabrizi M, Hoinoiu B, Petreuș DE, Seiman C (2025) Quercetin as a potential therapeutic agent for malignant melanoma-a review of current evidence and future directions. Medicina (Kaunas) 61(4):656

Article  PubMed  PubMed Central  Google Scholar 

Isacescu E, Chiroi P, Zanoaga O, Nutu A, Budisan L, Pirlog R, Atanasov AG, Berindan-Neagoe I (2023) Melanoma cellular signaling transduction pathways targeted by polyphenols action mechanisms. Antioxidants (Basel) 12(2):407

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Araujo JB, Kerkhoff VV, de Oliveira Maciel SFV, de Resen e Silva DT (2021) Targeting the purinergic pathway in breast cancer and its therapeutic applications. Purinergic Signal 17(2):179–200

Article  PubMed  PubMed Central  Google Scholar 

Kaur J, Dora S (2023) Purinergic signaling: diverse effects and therapeutic potential in cancer. Front Oncol 13:1058371

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orellano EA, Rivera OJ, Chevres M, Chorna NE, González FA (2010) Inhibition of neuronal cell death after retinoic acid-induced down-regulation of P2X7 nucleotide receptor expression. Mol Cell Biochem 337(1):83–99

Article  CAS  PubMed  Google Scholar 

Fujishita K, Koizumi S, Inoue K (2006) Upregulation of P2Y2 receptors by retinoids in normal human epidermal keratinocytes. Purinergic Signal 2(3):491–498

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bissacotti BF, da Silveira MV, Assmann CE, Copetti PM, Santos AFD, Fagan SB, da Silva AS (2025) Resveratrol alleviates inflammatory response through P2X7/NLRP3 signaling pathway: in silico and in vitro evidence from activated microglia. Pharmaceuticals 18(7):950

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14(1):1–18

Article  CAS  PubMed  Google Scholar 

Ochi-Ishi R, Nagata K, Inoue T, Tozaki-Saitoh H, Tsuda M, Inoue K (2014) Involvement of the chemokine CCL3 and the purinoceptor p2× 7 in the spinal cord in paclitaxel-induced mechanical allodynia. Mol Pain 10:1744–8069

Article  Google Scholar 

Mei C, Pan C, Xu L, Miao M, Lu Q, Yu Y, Lin P, Wu W, Ni F, Gao Y, Xu Y, Xu J, Chen X (2023) Trimethoxyflavanone relieves Paclitaxel-induced neuropathic pain via inhibiting expression and activation of P2X7 and production of CGRP in mice. Neuropharmacology 236:109584

Article  CAS  PubMed  Google Scholar 

Sandhu H, Cooper S, Hussain A, Mee C, Maddock H (2017) Attenuation of sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation. Eur J Pharmacol 814:95–105

Article  CAS  PubMed  Google Scholar 

Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS (2022) P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. J Pathol 256(2):149–163

Article  CAS  PubMed  Google Scholar 

Burnstock G, Di Virgilio F (2013) Purinergic signalling and cancer. Purinergic Signal 9(4):491–540

Article  CAS  PubMed  PubMed Central  Google Scholar